Adipose tissue in obesity and obstructive sleep apnoea

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 746-767

  Bonsignore, M R ^a,b   McNicholas, W T ^c   Montserrat, J M ^d   Eckel, J ^e  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Adipocyte; Dyslipidaemia; Hypoxia; Liver dysfunction; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; FATTY ACID; LEPTIN; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; SALICYLIC ACID DERIVATIVE; SIBUTRAMINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; AGE DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; GASTRIC BANDING; HUMAN; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; MENTAL DISEASE; METABOLIC REGULATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT SAFETY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SLEEP APNEA SYNDROME; THERAPY EFFECT; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; ANOXIA; DYSLIPIDEMIAS; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPOXYGENASE; MALE; MICE; OBESITY; OXIDATIVE STRESS; RATS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84857839017     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00047010     Document Type: Review

References (396)

1. Jensen MK, Chiuve SE, Rimm EB, et al. Obesity, behavioral lifestyle factors, and risk of acute coronary events. Circulation 2008; 117: 3062-3069.
2. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
3. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120.
4. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. J Am Med Assoc 2008; 299: 2401-2405. (Pubitemid 351749238)
5. Jackson-Leach R, Lobstein T. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes 2006; 1: 26-32.
6. Steinberger J, Moran A, Hong CP, et al. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr 2001; 138: 469-473. (Pubitemid 32319717)
7. Cali AM, Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab 2008; 93: Suppl. 1, s31-s36.
8. Trayhurn P, Wood S.Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355. (Pubitemid 40277057)
9. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867. (Pubitemid 46024993)
10. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008; 8: 923-934.
11. Einstein FH, Atzmon G, Yang XM, et al. Differential responses of visceral and subcutaneous fat depots to nutrients. Diabetes 2005; 54: 672-678. (Pubitemid 40322069)
12. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008; 100: 227-235.
13. Yang L, Hotamisligil GS. Stressing the brain, fattening the body. Cell 2008; 135: 20-22.
14. Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep 2008; 31: 619-626. (Pubitemid 351694250)
15. Marshall NS, Glozier N, Grunstein RR. Is sleep duration related to obesity? A critical review of the epidemiological evidence. Sleep Med Rev 2008; 12: 289-298.
16. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol 2005; 99: 1592-1599. (Pubitemid 43014371)
17. Li C, Ford ES, Zhao G, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med 2010; 51: 18-23.
18. Kaditis AG, Alexopoulos EI, Hatzi F, et al. Adiposity in relation to age as predictor of severity of sleep apnea in children with snoring. Sleep Breath 2008; 12: 25-31.
19. Tauman R, Gozal D. Obesity and obstructive sleep apnea in children. Paediatr Respir Rev 2006; 7: 247-259. (Pubitemid 44767192)
20. Redline S, Tishler PV, Schluchter M, et al. Risk factors for sleep-disordered breathing in children. Associationwith obesity, race, and respiratory problems. Am J Respir Crit CareMed 1999; 159: 1527-1532. (Pubitemid 29227864)
21. Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 144-153. (Pubitemid 351237872)
22. Levy P, Pepin JL, Arnaud C, et al. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 2008; 32: 1082-1095.
23. Bianchi MT, Cash SS, Mietus J, et al. Obstructive sleep apnea alters sleep stage transition dynamics. PLoS ONE 2010; 5: e11356.
24. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053. (Pubitemid 40386782)
25. Costa DJ, Mitchell R. Adenotonsillectomy for obstructive sleep apnea in obese children: a meta-analysis. Otolaryngol Head Neck Surg 2009; 140: 455-460.
26. Bhattacharjee R, Kheirandish-Gozal L, Mitchell RB, et al. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children. A multicenter retrospective study. Am J Respir Crit Care Med 2010; 182: 676-683.
27. Phillips BG, Hisel TM, Kato M, et al. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J Hypertens 1999; 17: 1297-1300. (Pubitemid 29509508)
28. Newman AB, Foster G, Givelber R, et al. Progression and regression of sleep-disordered breathing with changes in weight. Arch Intern Med 2005; 165: 2408-2413. (Pubitemid 41640854)
29. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. J Am Med Assoc 2000; 284: 3015-3021. (Pubitemid 32014738)
30. Grunstein RR, Wilcox I, Yang TS, et al. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 1993; 17: 533-540. (Pubitemid 23269132)
31. Welch KC, Foster GD, Ritter CT, et al. A novel volumetric magnetic resonance imaging paradigm to study upper airway anatomy. Sleep 2002; 25: 532-542. (Pubitemid 34787379)
32. Katsuki A, Sumida Y, Urakawa H, et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 2003; 26: 2341-2344. (Pubitemid 36993323)
33. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009; 6: 60-75.
34. Sans Capdevila O, Kheirandish-Gozal L, Dayyat E, et al. Pediatric obstructive sleep apnea: complications, management, and long-term outcomes. Proc Am Thorac Soc 2008; 5: 274-282. (Pubitemid 351237887)
35. Bonuck K, Parikh S, Bassila M. Growth failure and sleep disordered breathing: a review of the literature. Int J Pediatr Otorhinolaryngol 2006; 70: 769-778.
36. Bonsignore MR, Eckel J. Metabolic aspects of obstructive sleep apnoea syndrome. Eur Respir Rev 2009; 18: 113-124.
37. Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243-260.
38. Yin J, Gao Z, He Q, et al. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E333-E342.
39. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 2009; 33: 1467-1484.
40. Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab 2006; 8: 250-260.
41. Kent BD, Ryan S, McNicholas WT. The genetics of obstructive sleep apnoea. Curr Opin Pulm Med 2010; 16: 536-542.
42. Riha RL. Genetic aspects of the obstructive sleep apnoea/hypopnoea syndrome - is there a common link with obesity? Respiration 2009; 78: 5-17.
43. Riha RL, Gislasson T, Diefenbach K. The phenotype and genotype of adult obstructive sleep apnoea/hypopnoea syndrome. Eur Respir J 2009; 33: 646-655.
44. Lee D-E, Kehlenbrik S, Lee H, et al. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: 1210-1229.
45. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-853. (Pubitemid 46024991)
46. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines: energy regulation from the human perspective. J Nutr 2006; 136: Suppl. 7, 1935S-1939S. (Pubitemid 43973602)
47. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nature Rev Immunol 2011; 11: 85-97.
48. DiGirolamo M, Fine JB, Tagra K, et al. Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. Am J Physiol Regul Integr Comp Physiol 1998; 274: R1460-R1467.
49. Garaulet M, Hernandez-Morante JJ, Lujan J, et al. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans. Int J Obes 2006; 30: 899-905. (Pubitemid 43801188)
50. Jo J, Gavrilova O, Pack S, et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 2009; 5: e1000324.
51. Bowers RR, Festuccia WT, Song CK, et al. Sympathetic innervation of white adipose tissue and its regulation of fat cell number. Am J Physiol Regul Integr Comp Physiol 2004; 286: R1167-R1175. (Pubitemid 38661406)
52. Guo K, Mogen J, Struzzi S, et al. Preadipocyte transplantation: an in vivo study of direct leptin signaling on adipocyte morphogenesis and cell size. Am J Physiol Regul Integr Comp Physiol 2009; 296: R1339-R1347.
53. Kloting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506-E515.
54. Cinti S. Transdifferentiation properties of adipocytes. Am J Physiol Endocrinol Metab 2009; 297: E977-E986.
55. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007; 293: E444-E452. (Pubitemid 47205086)
56. Stephens M, Ludgate M, Rees A. Brown fat and obesity: the next big thing? Clin Endocrinol 2011; 74: 661-670.
57. Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008; 57: 367-371.
58. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419. (Pubitemid 36935533)
59. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062. (Pubitemid 41338752)
60. Bays HE, Gonzales-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343-368.
61. Walker GE, Verti B, Marzullo P, et al. Deep subcutaneous adipose tissue: a distinct abdominal adipose depot. Obesity 2007; 15: 1933-1943. (Pubitemid 47402225)
62. Ouwens DM, Sell H, Greulich S, et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010; 14: 2223-2234.
63. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752. (Pubitemid 41532612)
64. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600-605.
65. Karelis AD, St-Pierre DH, Conus F, et al. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569-2575. (Pubitemid 38766333)
66. Meigs JB, Wilson PWF, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912. (Pubitemid 44271734)
67. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes 2010; 34: 949-959.
68. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: Suppl. 1, S57-S63.
69. Lin J-W, Caffrey JL, Chang M-H, et al. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality - cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2010; 95: 4258-4267.
70. Velho S, Paccaud F, Waeber G, et al. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010; 64: 1043-1051.
71. Perrini S, Laviola L, Cignarelli A, et al. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia 2008; 51: 155-164. (Pubitemid 350197987)
72. Pittenger MF,Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
73. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 2005; 183: 13-30. (Pubitemid 40188033)
74. Ktotkiewski M, Sjostrom L, Bjorntorp P, et al. Regional adipose tissue cellularity in relation to metabolism in young and middle-aged women. Metabolism 1975; 24: 703-710.
75. Maury E, Ehala-Aleksejev K, Guiot Y, et al. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007; 293: E656-E665. (Pubitemid 47358976)
76. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann New York Acad Sci 2010; 1212: E1-E19.
77. Myers MGJ, Leibel RL, Seeley RJ, et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Met 2010; 21: 643-651.
78. Kanasaki K, Koya D. Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol 2011; 2011: 197636.
79. Malli F, Papaioannou AI, Gourgoulianis KI, et al. The role of leptin in the respiratory system: an overview. Respir Res 2010; 11: 152.
80. Ambrosini G, Nath AK, Sierra-Honigmann MR, et al. Transcriptional activation of the human leptin gene in response to hypoxia. J Biol Chem 2002; 277: 34601-34609.
81. Matarese G, Procaccini C, De Rosa V, et al. Regulatory T cells in obesity: the leptin connection. Trends Mol Med 2010; 16: 247-256.
82. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008; 117: 3238-3249.
83. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006; 281: 2654-2660. (Pubitemid 43845727)
84. Han SH, Sakuma I, Shin EK, et al. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009; 52: 126-140.
85. Esteve E, Ricart W, Fernandez-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4 and adiopnectin. Diabetes Care 2009; 32: Suppl. 2, S362-S367.
86. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15. (Pubitemid 38638516)
87. Hirose H, Yamamoto Y, Seino-Yoshihara Y, et al. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 2010; 17: 1201-1211.
88. Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089. (Pubitemid 34687474)
89. Chen B, Lam KS, Wang Y, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006; 341: 549-556. (Pubitemid 43152139)
90. Magalang UJ, Cruff JP, Rajappan R, et al. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp Clin Endocrinol Diabetes 2009; 117: 129-134.
91. Han SH, Quon MJ, Kim J. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531-538. (Pubitemid 46177440)
92. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91. (Pubitemid 23036092)
93. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801. (Pubitemid 44033299)
94. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 2007; 112: 61-67. (Pubitemid 47379852)
95. Solinas G, Karin M. JNK1 and IKK-beta: molecular links between obesity and metabolic dysfunction. FASEB J 2010; 24: 2596-2611.
96. Anand RJ, Gribar SC, Li J, et al. Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. J Leukoc Biol 2007; 82: 1257-1265. (Pubitemid 350133524)
97. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160.
98. Barbatelli MC, Pairsani V, Latini C, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008; 49: 1562-1568.
99. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184. (Pubitemid 46048464)
100. Wentworth JM, Naselli G, Brown WA, et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59: 1648-1656.
101. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296: E581-E591.
102. Varlamov O, Somwar R, Cornea A, et al. Single-cell analysis of insulin-regulated fatty acid uptake in adipocytes. Am J Physiol Endocrinol Metab 2010; 299: E486-E496.
103. O'Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010; 5: e9997.
104. Maumus M, Sengenes C, Decaunes P, et al. Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: influence of fat mass microenvironment and growth. J Clin Endocrinol Metab 2008; 93: 4098-4106.
105. HotamisligilGS. Inflammation and endoplasmic reticulumstress in obesity and diabetes. Int J Obes (Lond) 2008; 32: Suppl. 7, S52-S54.
106. Gao C-L, Zhua C, Zhao Y-P, et al. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes. Mol Cell Endocrinol 2010; 329: 25-33.
107. Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem 2008; 114: 267-276.
108. Regazzetti C, Peraldi P, Grémeaux T, et al. Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 2009; 58: 95-103.
109. Copps KD, White MF. Breathing room: the (un)natural history of adipose microhypoxia and insulin resistance. Diabetes 2009; 58: 26-27.
110. Pasarica M, Rood J, Ravussin E, et al. Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. J Clin Endocrinol Metab 2010; 95: 4052-4055.
111. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.
112. Dimitriadis G, Lambadiari V, Mitrou P, et al. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 2007; 30: 3128-3130.
113. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911. (Pubitemid 46525054)
114. Ye J, Gao Z, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293: E1118-E1128. (Pubitemid 47535846)
115. Wang B, Wood S, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455: 479-492. (Pubitemid 47624196)
116. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003; 278: 19575-19578. (Pubitemid 36799137)
117. Wood IS, Wang B, Lorente-Cebrián S, et al. Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes. Biochem Biophys Res Commun 2007; 361: 468-473. (Pubitemid 47193119)
118. Pérez de Heredia F, Wood IS, Trayhurn P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2 and MCT4) expression inhuman adipocytes. Pflugers Arch 2010; 459: 509-518.
119. Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol 2008; 198: 127-134. (Pubitemid 352038192)
120. Trayhurn P, Duncan JS, Wood AM, et al. Metallothionein gene expression and secretion in white adipose tissue. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2329-R2335.
121. Zhang X, Lam KS, Ye H, et al. Adipose tissue-specific inhibition of hypoxia-inducible factor 1alpha induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem 2010; 285: 32869-32877.
122. Almendros I, Farré R, Planas AM, et al. Tissue oxygenation in brain, muscle and fat in a rat model of sleep apnea: differential effect of obstructive apneas and intermittent hypoxia. Sleep 2011; 34: 1127-1133.
123. Nunemaker GS, Chen M, Pei H, et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet. Am J Physiol Endocrinol Metab 2008; 295: E1065-E1075.
124. Chakrabarti SK, Cole BK, Wen Y, et al. 12/15-Lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity 2009; 17: 1657-1663.
125. Wen YW, Gu J, Vandenhoff GE, et al. Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am J Physiol Heart Circ Physiol 2008; 294: H1933-H1938. (Pubitemid 351490623)
126. Zarrouki B, Soares AF, Guichardant M, et al. The lipid peroxidation end-product 4-HNE induces COX-2 expression through p38MAPK activation in 3T3-L1 adipose cell. FEBS Lett 2007; 581: 2394-2400. (Pubitemid 46764695)
127. Singh PS, Niemczyk M, Saini D, et al. Role of electrophilic lipid peroxidation product 4-hydroxynonenal in the development of obesity in mice. Biochemistry 2008; 47: 3900-3911. (Pubitemid 351431379)
128. Lui MM, Ip MS. Disorders of glucose metabolism in sleep-disordered breathing. Clin Chest Med 2010; 31: 271-285.
129. Doherty LS, Kiely JL, Swan V, et al. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127: 2076-2084.
130. Buchner NJ, Sanner BM, Borgel J, et al. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007; 176: 1274-1280. (Pubitemid 350256482)
131. Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-1085.
132. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-1078.
133. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6: e1000132.
134. Bonsignore MR, Esquinas C, Barceló A, et al. Metabolic syndrome, insulin resistance and sleepiness in real-life obstractive sleep apnoea. Eur Respir J 2011; [Epub ahead of print DOI: 10.1183/09031936.00151110].
135. Mortimore IL, Marshall I, Wraith PK, et al. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med 1998; 157: 280-283. (Pubitemid 28071293)
136. Kawaguchi Y, Fukumoto S, Inaba M, et al. Different impacts of neck circumference and visceral obesity on the severity of obstructive sleep apnea syndrome. Obesity 2011; 19: 276-282.
137. Preis SR, Massaro JM, Hoffmann U, et al. Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab 2010; 95: 3701-3710.
138. Onat A, Hergenç G, Yüksel H, et al. Neck circumference as a measure of central obesity: Associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. Clin Nutr 2009; 28: 46-51.
139. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study. Obesity (Silver Spring) 2011; 18: 2191-2198.
140. Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-676. (Pubitemid 34194755)
141. Punjabi NM, Sorkin JD, Katzel LI, et al. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002; 165: 677-682. (Pubitemid 34194756)
142. Coughlin SR, Mawdsley L, Mugarza JA, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-741. (Pubitemid 38647933)
143. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010; 5: e12065.
144. Gasa M, Salord N, Fortuna AM, et al. Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur Respir J 2011; 38: 1089-1097.
145. Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol 2009; 106: 1538-1544.
146. Pamidi S, Aronsohn RS, Tasali E. Obstructive sleep apnea: role in the risk and severity of diabetes. Best Pract Res Clin Endocrinol Metab 2010; 24: 703-715.
147. Wilcox I, McNamara SG, Collins FL, et al. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998; 53: Suppl. 3, S25-S28.
148. Punjabi NM, et al. Do sleep disorders and associated treatments impact glucose metabolism? Drugs 2009; 69: Suppl. 2, 13-27.
149. Vgontzas AN. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch Physiol Biochem 2008; 114: 211-223.
150. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5: 207-217. (Pubitemid 351237880)
151. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol 2005; 99: 1998-2007. (Pubitemid 41547203)
152. Pallayova M, Donic V, Tomori Z. Beneficial effects of severe sleep apnea therapy on nocturnal glucose control in persons with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 81: e8-e11.
153. Dawson A, Abel SL, Loving RT, et al. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 2008; 15: 538-542.
154. Aronsohn RS, Whitmore H, Van Cauter E, et al. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010; 181: 507-513.
155. Papanas N, Steiropoulos P, Nena E, et al. HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. Vasc Health Risk Manag 2009; 5: 751-756.
156. Drager LF, Queiroz EL, Lopes HF, et al. Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome. J Cardiometab Syndr 2009; 4: 89-95.
157. Ip MS, Lam KS, Ho C, et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-586.
158. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003; 22: 251-257. (Pubitemid 36986993)
159. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-1158. (Pubitemid 32269364)
160. Ozturk L, Unal M, Tamer L, et al. The association of the severity of obstructive sleep apnea with plasma leptin levels. Arch Otolaryngol Head Neck Surg 2003; 129: 538-540. (Pubitemid 36576396)
161. Tatsumi K, Kasahara Y, Kurosu K, et al. Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. Chest 2005; 127: 716-721. (Pubitemid 40775497)
162. Schafer H, Pauleit D, Sudhop T, et al. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 2002; 122: 829-839.
163. Patel SR, Palmer LJ, Larkin EK, et al. Relationship between obstructive sleep apnea and diurnal leptin rhythms. Sleep 2004; 27: 235-239. (Pubitemid 44138831)
164. Shimura R, Tatsumi K, Nakamura A, et al. Fat accumulation, leptin, and hypercapnia in obstructive sleep apnea-hypopnea syndrome. Chest 2005; 127: 543-549. (Pubitemid 40229315)
165. Sharma SK, Kumpawat S, Goel A, et al. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-17. (Pubitemid 46044133)
166. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 2008; 294: E778-E784. (Pubitemid 351483603)
167. Carneiro G, Togeiro SM, Ribeiro-Filho FF, et al. Continuous positive airway pressure therapy improves hypoadiponectinemia in severe obese men with obstructive sleep apnea without changes in insulin resistance. Metab Syndr Relat Disord 2009; 7: 537-542.
168. Kanbay A, Kokturk O, Ciftci TU, et al. Comparison of serum adiponectin and tumor necrosis factor-alpha levels between patients with and without obstructive sleep apnea syndrome. Respiration 2008; 76: 324-330.
169. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006; 64: 12-19.
170. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal falls and adiponectin levels in sleep apnea with abdominal obesity and impact of hypoxia-induced dysregulated adiponectin production in obese murine mesenteric adipose tissue. J Atheroscler Thromb 2011; 18: 240-247.
171. Drager LF, Bortolotto LA,Maki-Nunes C, et al. The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis 2010; 208: 490-495.
172. Trombetta IC, Somers VK, Maki-Nunes C, et al. Consequences of comorbid sleep apnea in the metabolic syndrome - implications for cardiovascular risk. Sleep 2010; 33: 1193-1199.
173. Drager LF, Genta PR, Pedrosa RP, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol 2010; 105: 1135-1139.
174. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9: 211-224. (Pubitemid 40694188)
175. Barcelo A, Barbe F, de la Pena M, et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008; 63: 946-950.
176. Nena E, Steiropoulos P, Papanas N, et al. Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath 2011; [Epub ahead of print DOI: 10.1007/s11325-010-0472-y].
177. Ronksley PE, Hemmelgarn BR, Heitman SJ, et al. Obstructive sleep apnoea is associated with diabetes in sleepy subjects. Thorax 2009; 64: 834-839.
178. Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Med Clin 2007; 2: 263-277.
179. Polotsky VY, Rubin AE, Balbir A, et al. Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6J mouse. Sleep Med 2006; 7: 7-16. (Pubitemid 43033539)
180. Farre R, Nacher M, Serrano-Mollar A, et al. Rat model of chronic recurrent airway obstructions to study the sleep apnea syndrome. Sleep 2007; 30: 930-933. (Pubitemid 47041397)
181. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-857. (Pubitemid 46631798)
182. Polotsky VY, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552: 253-264. (Pubitemid 37265483)
183. Xu J, Long YS, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic Biol Med 2009; 46: 783-790.
184. Yokoe T, Alonso LC, Romano LC, et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. J Physiol 2008; 586: 899-911. (Pubitemid 351194126)
185. Lam JCM, Lam B, Yao TJ, et al. A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010; 35: 138-145.
186. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156-162. (Pubitemid 38114528)
187. Khan SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 1996; 444: 840-846.
188. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
189. Sell H, Eckel J, Dietze-Schroeder D. Pathways leading to muscle insulin resistance: the muscle-fat connection. Arch Physiol Biochem 2006; 112: 105-113. (Pubitemid 44384778)
190. Taube A, Eckardt K, Eckel J. Role of lipid-derived mediators in skeletal muscle insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1004-E1012.
191. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
192. Yudkin JS, Eringa E, Stehouwer CDA. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-1820.
193. Marchesi C, Ebrahimian T, Angulo O, et al. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 2009; 54: 1384-1392.
194. Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009; 119: 1661-1670.
195. Pinnick KE, Collins SC, Londos C, et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring) 2008; 16: 522-530. (Pubitemid 351328001)
196. Rossi AP, Fantin F, Zamboni GA, et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obesity (Silver Spring) 2011; 19: 1747-1754.
197. van der Zijl NJ, Goossens GH, Moors CC, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011; 96: 459-467.
198. Vettor R, Milan G, Franzin C, et al. The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Regul Integr Comp Physiol 2009; 297: E987-E998.
199. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
200. Sell H, Dietze-Schroeder D, Kaiser U, et al. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006; 147: 2458-2467.
201. Aron A, Zedalis D, Gregg JM, et al. Potential clinical use of cardiopulmonary exercise testing in obstructive sleep apnea hypopnea syndrome. Int J Cardiol 2009; 132: 176-186.
202. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
203. Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010; 59: 347-357.
204. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657. (Pubitemid 34533559)
205. Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5: 27-42. (Pubitemid 38173592)
206. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
207. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005; 33: 138-144. (Pubitemid 41799792)
208. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. J Am Med Assoc 2003; 289: 3000-3004. (Pubitemid 37430103)
209. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395. (Pubitemid 39657013)
210. Hilden M, Christoffersen P, Juhl E, et al. Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-597. (Pubitemid 8149779)
211. Clark J. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: Suppl. 1, S5-S10. (Pubitemid 44309537)
212. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: Suppl. 1, S17-S29. (Pubitemid 44309539)
213. Hesham A, Kader H. Nonalcoholic fatty liver disease in children living in the obesogenic society. World J Pediatr, 2009: 245-254.
214. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838. (Pubitemid 351364588)
215. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435.
216. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-1987.
217. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100: 3077-3082. (Pubitemid 36356542)
218. Donnelly KL, Smith CI, Schwarzenberger SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351. (Pubitemid 40629054)
219. Gonzales-Yanes C, Sanchez-Margalet V. Signalling mechanisms regulating lipolysis. Cell Signal 2006; 18: 401-408.
220. Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 568-576. (Pubitemid 351173040)
221. Lavie L. Oxidative stress-a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis 2009; 51: 303-312.
222. Barceló A, Piérola J, de la Peña M, et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnea. Eur Respir J 2011; 37: 1418-1423.
223. Jun JC, Drager LF, Najjar SS, et al. Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. Sleep 2011; 34: 1207-1213.
224. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol 2010; 16: 4243-4252.
225. Singh H, Pollock R, Uhanova J, et al. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 2338-2343. (Pubitemid 43106390)
226. Mathurin P, Durand F, Ganne N, et al. Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology 1995; 109: 1682-1684.
227. Saibara T, Nozaki Y, Nemoto Y, et al. Low socioeconomic status and coronary artery disease. Lancet 2002; 359: 980.
228. Trakada G, Gogos C, Tsiamita M, et al. A case of ischemic hepatitis. Sleep Breath 2004; 8: 155-159. (Pubitemid 39386520)
229. Strauss S, Gavish E, Gottlieb P, et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189: W320-W323.
230. de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14: 1415-1418.
231. Mehta SR, Thomas EL, Bell JD, et al. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14: 3476-3483.
232. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
233. Polotsky VY, Patil SP, Savransky V, et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179: 228-234.
234. Kallwitz ER, Herdegen J, Madura J, et al. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol 2007; 41: 918-921. (Pubitemid 350307079)
235. Mishra P, Nugent C, Afendy A, et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 2008; 28: 1080-1086.
236. Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-1923. (Pubitemid 351945559)
237. Jouët P, Sabaté JM, Maillard D, et al. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. Obes Surg 2007; 17: 478-485.
238. Daltro C, Cotrim HP, Alves E, et al. Nonalcoholic fatty liver disease associated with sleep apnea: just a coincidence? Obes Surg 2010; 20: 1536-1543.
239. Tanné F, Gagnadoux F, Chazouillères O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-1296.
240. Tatsumi K, Saibara T. Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 100-104. (Pubitemid 41799784)
241. Norman D, Bardwell WA, Arosemena F, et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 2008; 31: 121-126.
242. Chin K, Nakamura T, Takahashi K, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med 2003; 114: 370-376. (Pubitemid 36513685)
243. Kohler M, Pepperell JC, Davies RJ, et al. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration 2009; 78: 141-146.
244. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, et al. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008; 133: 92-99.
245. Verhulst SL, Jacobs S, Aerts L, et al. Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? Sleep Breath 2009; 13: 207-210.
246. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007; 293: G871-G877. (Pubitemid 47605939)
247. Takayama F, Egashira T, Kawasaki H, et al. A novel animal model on nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH. J Clin Biochem Nutr 2009; 45: 335-340.
248. Savransky V, Nanayakkara A, Vivero A, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2007; 45: 1007-1013. (Pubitemid 46631569)
249. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes melitus. Am J Med 2003; 115: Suppl. 8A, 24S-28S.
250. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009; 4: 113-119.
251. Chirovsky DR, Fedirko V, Cui Y, et al. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 404-423.
252. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
253. Adiels M, Olofsson S-O, Taskinen M-R, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-1236.
254. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 2007; 132: 2181-2190. (Pubitemid 46693753)
255. Olofsson S-O, Bore'n J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258: 395-410. (Pubitemid 41546555)
256. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nature Rev Endocrinol 2010; 6: 335-346.
257. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010; 45: 907-914.
258. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009; 16: 145-154.
259. Newman AB, Nieto FJ, Guidry U, et al. Relation of sleep disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001; 154: 50-59. (Pubitemid 32565686)
260. Roche F, Sforza E, Pichot V, et al. Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. Sleep Med 2009; 10: 882-886.
261. McArdle N, Hillman D, Beilin L, et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007; 175: 190-195. (Pubitemid 46115091)
262. Dorkova Z, Petrasova D, Molcanyiova A, et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-692.
263. Gozal D, Sans Capdevila O, Kheirandish-Gozal L. Metabolic alterations and systemic inflammation in obstructive sleep apnea among non-obese and obese pre-pubertal children. Am J Resp Crit Care Med 2008; 177: 1142-1149. (Pubitemid 351717574)
264. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132: 843-851.
265. Iesato K, Tatsumi K, Saibara T, et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J 2007; 71: 1293-1298. (Pubitemid 47195349)
266. Czerniawska J, Bielen P, Plywaczewski R, et al. Metabolic abnormalities in obstructive sleep apnea patients. Pneumonol Alergol Pol 2008; 76: 340-347.
267. Lefebvre B, Pepin JL, Baguet JP, et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008; 32: 113-120.
268. Tsioufis C, Thomopoulos K, Dimitriadism K, et al. The incremental effect of obstructive sleep apnoea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects. J Hypertens 2007; 25: 141-146. (Pubitemid 44885675)
269. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613-618. (Pubitemid 41232973)
270. Tan KC, Chow WS, Lam JC, et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-382. (Pubitemid 43049723)
271. Tokuda F, Sando Y, Matsui H, et al. Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. Intern Med 2008; 47: 1843-1849.
272. Li J, Grigoryev DN, Ye SQ, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 2005; 99: 1643-1648. (Pubitemid 41547158)
273. Li J, Thorne LN, Punjabi NM. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706. (Pubitemid 41416339)
274. Li J, Savransky V, Nanayakkara A, et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-563. (Pubitemid 46220883)
275. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290-1297. (Pubitemid 46905755)
276. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131. (Pubitemid 34496588)
277. Li J, Nanayakkara A, Jun J, et al. Effect of deficiency in SREBP cleavage activating protein on lipid metabolism during intermittent hypoxia. Physiol Genomics 2007; 31: 273-280. (Pubitemid 350014405)
278. Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103: 1173-1180.
279. Li J, Bosch-Marce M, Nanayakkara A, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 2006; 25: 450-457.
280. de Glisezinski I, Crampes F, Harant I, et al. Decrease of subcutaneous adipose tissue lipolysis after exposure to hypoxia during a simulated ascent of Mt Everest. Pflügers Arch 1999; 439: 134-140.
281. Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol 2009; 29: 4527-4538.
282. Drager LF, Li J, Shin MK, et al . Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J 2011; [Epub ahead of print DOI: 10.1093/eurheartj/ehr097].
283. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137-2142. (Pubitemid 35192822)
284. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-E288.
285. Hall MH, Muldoon MF, Jennings JR, et al. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. Sleep 2008; 31: 635-643. (Pubitemid 351694252)
286. Jennings JR, Muldoon MF, Hall MH, et al. Self-reported sleep quality is associated with the metabolic syndrome. Sleep 2007; 30: 219-223.
287. Kaneita Y, Uchiyama M, Yoshiike N, et al. Associations of usual sleep duration with serum lipid and lipoprotein levels. Sleep 2008; 31: 645-652. (Pubitemid 351694253)
288. Dochi M, Suwazono Y, Sakata K, et al. Shift work is a risk factor for increased total cholesterol level: a 14-year prospective cohort study in 6886 male workers. Occup Environ Med 2009; 66: 592-597.
289. Sookoian S, Gemma C, Fernández Gianotti T, et al. Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. J Intern Med 2007; 261: 285-292.
290. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007; 30: 1667-1673. (Pubitemid 350234745)
291. Beihl DA, Liese AD, Haffner SM. Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol 2009; 19: 351-357.
292. Chen JC, Brunner RL, Ren H, et al. Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke 2008; 39: 3185-3192.
293. Brown DL, Feskanich D, Sánchez BN, et al. Rotating night shift work and the risk of ischemic stroke. Am J Epidemiol 2009; 169: 1370-1377.
294. Fujino Y, Iso H, Tamakoshi A, et al. A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. Am J Epidemiol 2006; 164: 128-135. (Pubitemid 43992178)
295. Puttonen S, Kivimäki M, Elovainio M, et al. Shift work in young adults and carotid artery intima-media thickness: the Cardiovascular Risk in Young Finns study. Atherosclerosis 2009; 205: 608-613.
296. Lauderdale DS, Knutson KL, Rathouz PJ, et al. Cross-sectional and longitudinal associations between objectively measured sleep duration and body mass index: the CARDIA Sleep Study. Am J Epidemiol 2009; 170: 805-813.
297. Patel SR, Blackwell T, Redline S, et al. The association between sleep duration and obesity in older adults. Int J Obes 2008; 32: 1825-1834.
298. Touchette E, Petit D, Tremblay RE, et al. Associations between sleep duration patterns and overweight/obesity at age 6. Sleep 2008; 31: 1507-1514.
299. Stranges S, Cappuccio FP, Kandala NB, et al. Cross-sectional versus prospective associations of sleep duration with changes in relative weight and body fat distribution: the Whitehall II Study. Am J Epidemiol 2008; 167: 321-329. (Pubitemid 351197591)
300. Everson C, Szabo A. Recurrent restriction of sleep and inadequate recuperation induced both adaptive changes and pathological outcomes. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1430-R1440.
301. Nedeltcheva AV, Kessler L, Imperial J, et al. Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. J Clin Endocrinol Metab 2009; 94: 3242-3250.
302. Nedeltcheva AV, Kilkus JM, Imperial J, et al. Sleep curtailment is accompanied by increased intake of calories from snacks. Am J Clin Nutr 2009; 89: 126-133.
303. Spiegel K, Tasali E, Leproult R, et al. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009; 5: 253-261.
304. Tasali E, Leproult R, Ehrmann DA, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 2008; 105: 1044-1049. (Pubitemid 351282078)
305. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004; 89: 2119-2126. (Pubitemid 38619840)
306. Bray MS, Young ME. Circadian rhythms in the development of obesity: potential role for the circadian clock within the adipocyte. Obes Rev 2007; 8: 169-181. (Pubitemid 46239443)
307. Young ME, Bray MS. Potential role for peripheral circadian clock dyssynchrony in the pathogenesis of cardiovascular dysfunction. Sleep Med Rev 2007; 8: 656-667. (Pubitemid 47181211)
308. Prasai MJ, Goerge JT, Scott EM. Molecular clocks, type 2 diabetes and cardiovascular disease. Diabetes Vasc Dis Res 2008; 5: 89-95. (Pubitemid 351839279)
309. Duez H, Staels B. Rev-erba: an integrator of circadian rhythms and metabolism. J Appl Physiol 2009; 107: 1972-1980.
310. Scheer FA, Hilton MF, Mantzoros CS, et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009; 106: 4453-4458.
311. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010; 137: 95-101.
312. Perrini S, Leonardini A, Laviola L, et al. Biological specificity of visceral adipose tissue and therapeutic interventions. Arch Physiol Biochem 2008; 114: 277-286.
313. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
314. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: the follow-up results of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
315. Pannain S, Mokhlesi B. Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism. Best Pract Res Clin Endocrinol Metab 2010; 24: 745-761.
316. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systematic review and meta-analysis. J Am Med Assoc 2004; 292: 1724-1737. (Pubitemid 39346675)
317. Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621-635. (Pubitemid 47575601)
318. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2008; 4: Suppl. 43, S47-S55. (Pubitemid 351689962)
319. Sjöström L, Narbro K, Sjöström D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
320. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100. (Pubitemid 43228239)
321. Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, et al. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. BMC Gastroenterol 2009; 9: 75.
322. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705. (Pubitemid 46048557)
323. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493. (Pubitemid 46871159)
324. Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
325. Alhusaini S, McGee K, Schisano B, et al. Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: salicylate alleviates this stress. Biochem Biophys Res Commun 2010; 397: 472-478.
326. Fernández-Real JM, López-Bermejo A, Ropero AB, et al. Salicylates increase insulin secretion in healthy obese subjects. J Clin Endocrinol Metab 2008; 93: 2523-2530.
327. Fleischman A, Shoelson SE, Bernier R, et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31: 289-294. (Pubitemid 351213338)
328. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52: 385-393.
329. Li M, Cheung BMY. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68: 804-810.
330. Redenius R, Murphy C, O'Neill E, et al. Does CPAP lead to change in BMI? J Clin Sleep Med 2008; 4: 205-209. (Pubitemid 352039429)
331. Reichmuth KJ, Austin D, Skatrud JB, et al. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172: 1590-1595. (Pubitemid 43076551)
332. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720-727. (Pubitemid 46554622)
333. Vgontzas AN, Zoumakis E, Bixler EO, et al. Selective effects of CPAP on sleep-apnoea associated manifestations. Eur J Clin Invest 2008; 38: 585-595. (Pubitemid 352019140)
334. West SD, Nicoll DJ, Wallace TM, et al. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974. (Pubitemid 350084496)
335. Steiropoulos P, Papanas N, Nena E, et al. Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev 2010; 6: 155-166.
336. Drager LF, Jun JC, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2010; 17: 161-165.
337. Cuhadaroglu C, Utkusavas A, Ozturk L, et al. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. Lung 2009; 187: 75-81.
338. Barcelo A, Barbe F, Llompart E, et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med 2005; 171: 183-187. (Pubitemid 40105419)
339. Sanner BM, Kollhosser P, Buechner N, et al. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur Respir J 2004; 23: 601-604. (Pubitemid 38456004)
340. Trenell MI, Ward JA, Yee BJ, et al. Influence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Diabetes Obes Metab 2007; 9: 679-687. (Pubitemid 47261849)
341. Chin K, Nakamura T, Shimizu K, et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000; 109: 562-567.
342. Chin K, Shimizu K, Nakamura T, et al. Changes in intraabdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999; 100: 706-712. (Pubitemid 29383639)
343. Robinson GV, Pepperell JC, Segal HC, et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004; 59: 777-782. (Pubitemid 39215375)
344. Shneerson J, Wright J. Lifestyle modification for obstructive sleep apnoea. Cochrane Database of Syst Rev 2001; 1: CD002875.
345. Tuomilehto HP, Seppä JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009; 179: 320-327.
346. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes. Arch Intern Med 2009; 169: 1619-1626.
347. Johansson K, Neovius M, Lagerros YT, et al. Effect of a very low energy diet on moderate to severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ 2009; 339: b4609.
348. Johansson K, Hemmingsson E, Harlid R, et al. Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study. BMJ 2011; 342: d3017.
349. Nerfeldt P, Nilsson BY, Mayor L, et al. A two-year weight reduction program in obese sleep apnea patients. J Clin Sleep Med 2010; 6: 479-486.
350. Grunstein RR, Stenlöf K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30: 703-710.
351. Dixon JB, Schachter LM, O'Brien PE. Polysomnography before and after weight loss in obese patients with severe sleep apnea. Int J Obes 2005; 29: 1048-1054. (Pubitemid 41192211)
352. Haines KL, Nelson LG, Gonzales R, et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery 2007; 141: 354-358. (Pubitemid 46356437)
353. Rao A, Tey BH, Ramalingam G. Obstructive sleep apnoea (OSA) patterns in bariatric surgical practice and response of OSA to weight loss after laparoscopic adjustable gastric banding (LABG). Ann Acad Med Singapore 2009; 38: 587-593.
354. Martinez D, Basile BR. Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study. Sleep Med Clin 2005; 6: 467-470. (Pubitemid 41245370)
355. Yee BJ, Phillips CL, Banerjee D, et al. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes 2007; 31: 161-168. (Pubitemid 46006030)
356. Phillips CL, Yee BJ, Trenell MI, et al. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med 2009; 5: 416-421.
357. Ferland A, Poirier P, Sériès F. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. Eur Respir J 2009; 34: 694-701.
358. Williams G. Withdrawal of sibutramine in Europe. Br Med J 2010; 340: c824.
359. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008; 5: 173-178. (Pubitemid 351237875)
360. Han JC, Lawlor DA, Kimm SYS. Childhood obesity. Lancet 2010; 375: 1737-1748.
361. Mohamadi A, Cooke DW. Type 2 diabetes mellitus in children and adolescents. Adolesc Med State Art Rev 2010; 21: 103-119.
362. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656. (Pubitemid 28267909)
363. Spicuzza L, Leonardi S, La Rosa M. Pediatric sleep apnea: early onset of the 'syndrome'? Sleep Med Rev 2009; 13: 111-122.
364. Gozal D. Sleep, sleep disorders and inflammation in children. Sleep Med 2009; 10: Suppl. 1, S12-S16.
365. Dayyat E, Kheirandish-Gozal L, Sans Capdevila O, et al. Obstructive sleep apnea in children: relative contributions of body mass index and adenotonsillar hypertrophy. Chest 2009; 136: 137-144.
366. Wang JH, Chung YS, Cho YW, et al. Palatine tonsil size in obese, overweight, and normal-weight children with sleep-disordered breathing. Otolaryngol Head Neck Surg 2010; 142: 516-519.
367. Tauman R, Gulliver TE, Krishna J, et al. Persistence of obstructive sleep apnea syndrome in children after adenotonsillectomy. J Pediatr 2006; 149: 803-808. (Pubitemid 44809273)
368. Kohler MJ, Thormaehlen S, Kennedy JD, et al. Differences in the association between obesity and obstructive sleep apnea among children and adolescents. J Clin Sleep Med 2009; 5: 506-511.
369. Arens R, Sin S, Nandalike K, et al. Upper airway structure and body fat composition in obese children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2011; 183: 782-787.
370. Eliot SK, Carolyn MDA. Pediatric obstructive sleep apnea syndrome. Clin Chest Med 2010; 31: 221-234.
371. Zimmet P, Alberti G, Kaufman F, et al. The metabolic syndrome in children and adolescents. Lancet 2007; 369: 2059-2061. (Pubitemid 46935928)
372. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374. (Pubitemid 38702847)
373. Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-827. (Pubitemid 36988016)
374. de Ferranti SD, Gauvreau K, Ludwig DS, et al.; Prevalence of the metabolic syndrome in American adolescents: findings from the third National Health and Nutrition Examination Survey. Circulation 2004; 110: 2494-2497. (Pubitemid 39407358)
375. Kelishadi R, Cook SR, Amra B, et al. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 2009; 204: 538-543.
376. Cali AM, Caprio S. Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. Horm Res 2009; 71: 2-7.
377. Li AM, Chan MH, Chan DF, et al. Insulin and obstructive sleep apnea in obese Chinese children. Pediatr Pulmonol 2006; 41: 1175-1181. (Pubitemid 44893871)
378. Verhulst SL, Schrauwen N, Haentjens D, et al. Sleep disordered breathing and the metabolic syndrome in overweight and obese children and adolescents. J Pediatr 2007; 150: 608-612. (Pubitemid 46755804)
379. Hannon TS, Lee S, Chakravorty S, et al. Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. Int J Pediatr Obes 2011; 6: 157-160.
380. Redline S, Storfer-Isser A, Rosen CL, et al. Association between metabolic syndrome and sleep-disordered breathing in adolescents. Am J Respir Crit Care Med 2007; 176: 401-408. (Pubitemid 47267475)
381. Verhulst SL, Rooman RP, Van Gaal L, et al. Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents? Int J Obes (Lond) 2009; 33: 8-13.
382. Tsaoussoglou M, Bixler EO, Calhoun S, et al. Sleep-disordered breathing in obese children is associated with prevalent excessive daytime sleepiness, inflammation, and metabolic abnormalities. J Clin Endocrinol Metab 2010; 95: 143-150.
383. Dubern B, Aggoun Y, Boule M, et al. Arterial alterations in severely obese children with obstructive sleep apnoea. Int J Pediatr Obes 2010; 5: 230-236.
384. Gozal D, Kheirandish-Gozal L. Obesity and excessive daytime sleepiness in prepubertal children with obstructive sleep apnea. Pediatrics 2009; 123: 13-18.
385. Alexopoulos EI, Gletsou E, Kostadima E, et al. Effects of obstructive sleep apnea severity on serum lipid levels in Greek children with snoring. Sleep Breath 2011; 15: 625-631.
386. Tauman R, O'Brien LM, Ivanenko A, et al. Obesity rather than severity of sleep-disordered breathing as the major determinant of insulin resistance and altered lipidemia in snoring children. Pediatrics 2005; 116: 66-73.
387. Kelly A, Dougherty S, Cucchiara A, et al. Catecholamines, adiponectin, and insulin resistance as measured by HOMA in children with obstructive sleep apnea. Sleep 2010; 33: 1185-1191.
388. Deboer MD, Mendoza JP, Liu L, et al. Increased systemic inflammation overnight correlates with insulin resistance among children evaluated for obstructive sleep apnea. Sleep Breath 2011; [Epub ahead of print DOI: 10.1007/s11325-011-0499-8].
389. Tauman R, Serpero LD, Sans Capdevila O, et al. Adipokines in children with sleep-disordered breathing. Sleep 2007; 30: 443-449.
390. Li AM, Ng C, Ng SK, et al. Adipokines in children with obstructive sleep apnea and the effects of treatment. Chest 2010; 137: 529-535.
391. Verhulst SL, Franckx H, Van Gaal L, et al. The effect of weight loss on sleep-disordered breathing in obese teenagers. Obesity (Silver Spring) 2009; 17: 1178-1183.
392. Roemmich JN, Barkley JE,D'Andrea L, et al. Increases in overweight after adenotonsillectomy in overweight children with obstructive sleep-disordered breathing are associated with decreases in motor activity and hyperactivity. Pediatrics 2006; 117: e200-e208. (Pubitemid 46074643)
393. Apostolidou MT, Alexopoulos EI, Damani E, et al. Absence of blood pressure, metabolic, and inflammatory marker changes after adenotonsillectomy for sleep apnea in Greek children. Pediatr Pulmonol 2008; 43: 550-560. (Pubitemid 351813008)
394. Waters KA, Sitha S, O'Brien LM, et al. Follow-up on metabolic markers in children treated for obstructive sleep apnea. Am J Respir Crit Care Med 2006; 174: 455-460. (Pubitemid 44223127)
395. Vijay LM, Naga C. Obstructive sleep apnea and nonalcoholic fatty liver disease: causal association or just a coincidence? Gastroenterology 2008; 134: 2178-2179.
396. Nakra N, Bhargava S, Dzuira J, et al. Sleep-disordered breathing in children with metabolic syndrome: the role of leptin and sympathetic nervous system activity and the effect of continuous positive airway pressure. Pediatrics 2008; 122: e634-e642.